Komori
Share Issuance and Disposal4889Renascience Inc.Pharmaceuticals

Notice Concerning the Reduction of Capital Reserve and Disposition of Surplus

¥1,136,328,774 of capital reserve will be transferred to other capital surplus, and the entire amount will be applied to offset the deficit in retained earnings carried forward. The number of shares and net assets will remain unchanged.

Worth reading
23Immaterial
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1136328774
¥
Wording
Conditional
How definitive the wording is.

Details of issuance or disposal

発行済株式総数

No change

Impact on Business Performance
This will have no impact on business performance.
Details of issuance or disposal
ItemDetails
Total number of issued sharesNo change
Impact on Business PerformanceThis will have no impact on business performance.
Items this document does not state (26)
Type of issuance or disposalNumber of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offering

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To offset the deficit in retained earnings carried forward and strengthen the Company's financial position.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Reduction of Capital Reserve and Disposition of Surplus | Renascience Inc. (4889) timely disclosure | Komori